Filter
987
Text search:
Johnson,
P.
Featured
90
208
Language
787
78
76
42
20
15
11
6
4
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Document type
479
227
165
66
19
17
8
2
1
1
1
Countries
45
39
25
23
22
16
16
15
15
14
13
13
11
11
10
10
10
9
9
9
9
8
8
7
7
7
7
6
6
6
6
6
6
5
5
5
5
5
4
4
4
4
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
131
54
37
35
18
17
14
12
9
7
7
6
5
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Publication Years
299
601
84
3
Category
296
82
59
56
32
14
9
1
Toolboxes
140
81
47
46
46
42
42
38
35
28
26
20
18
18
13
11
10
9
9
8
5
4
2
1
1
A Global Access Framework for Country-Led.
ResponsesThis 2030 Prevention access framework focuses on one of those top-line targets, which covers primary prevention and requires that 90% of people in need of HIV prevention are using effective prevention options by 2030. This target is disaggregated
...
into 15 second-line prevention targets for specific populations and programmes.
The 2030 Prevention Access Framework presents in greater detail the milestones and actions for achieving these targets––all of which are grounded in the three priorities of the Global AIDS Strategy: country-led, resilient and sustainable HIV responses; people-focused services, and community leadership
more
Western Pacific surveillance and response journal: WPSAR Vol.14 No. 6, Special Edition, pp.1-17
The purpose of this interim guidance is to provide recommendations for planning and implementing RCCE activities that protect and empower communities during MVD outbreaks. The guidance is designed for national and subnational health responders involved in RCCE for MVD readiness and response. It is a
...
lso relevant to other stakeholders, such as partner organizations, ministries (such as those involved in social protection), and academics, who contribute to RCCE activities. The document is meant to be adapted alongside national multi-risk/ multisectoral plans, leveraging existing expertise, coordination mechanisms and partnerships.
more
Filoviral hemorrhagic fever (FHF) is caused by ebolaviruses and marburgviruses, which both belongto the family Filoviridae. Egyptian fruit bats (Rousettus aegyptiacus) are the most likely natural reservoir for marburg viruses and entry into caves and mines that they stay in has often been associated
...
with outbreaks of MVD. On the other hand, the natural reservoir for ebola viruses remains elusive;however, handling of wild animal carcasses has been associated with some outbreaks of EVD. In thelast two decades, there has been an increase in the incidence of FHF outbreaks in Africa, some beingcaused by a newly found virus and some occurring in previously unaffected areas such as Guinea, Liberia and Sierra Leone, in which the most recent EVD outbreak occurred in 2014. Indeed, the predicted geographic distribution of filoviruses and their potential reservoirs in Africa includes manycountries in which FHF has not been reported. To minimize the risk of virus dissemination inpreviously unaffected areas, there is a need for increased investment in health infrastructure in African countries, policies to facilitate collaboration between health authorities from different countries, implementation of outbreak control measures by relevant multi-disciplinary teams and education of the populations at risk.
more
This review article provides a comprehensive overview of Ebola Virus Disease (EVD), covering its epidemiology, clinical presentation, diagnosis, treatment, and prevention. It explains that Ebola is a severe zoonotic infection caused by the Ebola virus, most likely originating from fruit bats and tra
...
nsmitted to humans through contact with infected animals or body fluids. The article summarizes the history of Ebola outbreaks in Africa, including the major West African epidemic of 2013–2016 and subsequent outbreaks in the Democratic Republic of Congo. It describes the disease’s clinical course, ranging from nonspecific flu-like symptoms to severe dehydration, multiorgan failure, shock, and death. The authors discuss diagnostic methods, supportive and intensive care management, emerging antiviral therapies and monoclonal antibodies, as well as the development and use of Ebola vaccines. The review also highlights the importance of infection control, contact tracing, community engagement, safe burial practices, and healthcare worker protection in controlling outbreaks. Finally, it addresses long-term complications in survivors and the persistence of Ebola virus in certain body compartments, particularly semen, which may contribute to delayed transmission.
more
This review article examines 42 years of Ebola virus disease (EVD) outbreaks in Sub-Saharan Africa, from 1976 to 2019. The authors analyze the epidemiology, geographical distribution, mortality rates, and response strategies associated with 34 Ebola outbreaks across 11 African countries. The review
...
identifies key challenges in controlling Ebola, including weak health systems, limited surveillance and laboratory capacity, sociocultural practices, environmental changes, and community mistrust. It also discusses advances in diagnostics, treatments, and vaccines, and emphasizes the importance of a One Health approach, community engagement, effective communication, and stronger healthcare systems to improve preparedness, prevention, and response to future Ebola outbreaks.
more
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp
...
fehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist.
more
